Arrowhead Cleared to Begin Phase IIa Trial of HBV Drug | GenomeWeb

Arrowhead Research this week announced that it has received clearance from regulators in Hong Kong to begin a phase IIa trial of its siRNA-based hepatitis B treatment ARC-520.

The single-dose, dose-escalation trial is designed to determine the drug's ability to suppress hepatitis B surface antigen in combination with the oral antiviral agent entecavir in chronic HBV patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.